WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Breaking Media, Inc | August 03, 2018
An Israeli drugmaker has come out of stealth and enrolled the first patient in its Phase III study that aims to treat an eye disorder using a drug derived from a type of tree resin. Regenera Pharma announced Thursday the enrollment of the first patient in the 234-patient study of RPh201 in nonarteritic anterior ischemic optic neuropathy, or NAION, which is a type of stroke of the optic nerve. The drug is a patented extract of gum mastic – long used in traditional medicine and in nutraceuti...
MSN | February 25, 2020
OxyContin maker Purdue Pharma launched an ad campaign Monday to tell people harmed by their powerful prescription opioid where they can file claims against the company. The $23.8 million campaign is part of Purdue's bankruptcy proceedings as it tries to resolve close to 3,000 lawsuits over its role in the opioid crisis. Notifying people who may have claims against a company is a standard part of a bankruptcy case. But Purdue’s efforts —worked out with input from a committee of cr...
TechStartups.com | March 12, 2019
The global pharmaceutical market is over $1 trillion marks and is projected to grow at 6.3% CAGR through 2022. With all the technology advancements in drug research and medicine, the pharmaceutical supply chain is still lagging behind in digital transformation compared to other industries. Getting the required ingredients and raw materials from suppliers to the buyer is rife with complexity and cumbersome processes. It is a market that is ripe for disruption. Enter Pharma offer, a Dutch pharma s...
Pharmacy Business | January 14, 2020
The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE